ClinicalTrials.gg
RecruitingNCT07448116Updated Mar 4, 2026

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

A Phase 1/2 interventional study of MCLA-129 and Ensartinib in Solid Advanced Tumor, sponsored by Betta Pharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Betta Pharmaceuticals Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
164
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.

Read the detailed description

This is a multi-center, open-label Phase I/II clinical study of MCLA-129 in combination with ensartinib in patients with advanced solid tumors to evaluate the efficacy, safety, and pharmacokinetics of MCLA-129 in combination with ensartinib. The study is divided into two parts: Phase I is a dose-exploration study to confirm the safe tolerability and recommended Phase II combination dose (RP2CD) of MCLA-129 in combination with ensartinib, and Phase II is a parallel cohort expansion study to further evaluate the efficacy, safety, and pharmacokinetics (PK) of MCLA-129 in combination with ensartinib in patients with advanced solid tumors in cohorts.

Primary Objectives of Phase I:

To evaluate the safety and tolerability of MCLA-129 in combination with ensartinib in patients with advanced solid tumors, and to determine potential dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) To determine the recommended Phase II combination dose (RP2CD) of MCLA-129 in combination with ensartinib.

Secondary Objectives of Phase I:

To evaluate the pharmacokinetic (PK) profile of MCLA-129 in combination with ensartinib in patients with advanced solid tumors To preliminarily evaluate the efficacy of MCLA-129 in combination with ensartinib in patients with advanced solid tumors To evaluate the immunogenicity of MCLA-129

Primary Objectives of Phase II:

To evaluate the efficacy of MCLA-129 in combination with ensartinib at the RP2CD in patients with advanced solid tumors across different cohorts.

Secondary Objectives of Phase II:

To evaluate the safety of MCLA-129 in combination with ensartinib at the RP2CD in patients with advanced solid tumors.

To evaluate the immunogenicity of MCLA-129.

02

Conditions studied

  • Solid Advanced Tumor
03

In context

Lead sponsor

Betta Pharmaceuticals Co., Ltd. is the lead sponsor of 79 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects should be aged 18-75 years (both inclusive), regardless of gender.
  • Subjects must have or cytologically confirmed, locally advanced or solid tumors (including but not limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck (primary site of oral cavity, oropharynx, hypopharynx, or larynx), gastric/gastroesophageal junction adenocarcinoma, etc.) that are not amenable to curative therapy.
  • Subjects must have MET amplification or MET overexpression as confirmed by the tests conducted by local or central laboratory.[MET amplification for Cohort 1 and Cohort 3 is defined as: MET copy number (CN) ≥ 5 by next-generation sequencing (NGS); or MET gene copy number (GCN) ≥ 5 or MET/CEP7 ≥ 2 by fluorescence in situ hybridization (FISH). MET amplification for Cohort 2 is defined as: MET copy number (CN) ≥ 3 by next-generation sequencing (NGS); or MET gene copy number (GCN) ≥ 3 or MET/CEP7 ≥ 2 by fluorescence in situ hybridization (FISH). MET overexpression is defined as 2+ or 3+ staining of ≥50% of tumor cells in tumor tissue samples by immunohistochemistry (IHC).]
  • For phase I study: subjects must meet the following conditions: with disease progression or intolerance to standard treatment after standard treatment, or evaluated by the investigator as ineligible for platinum-based chemotherapy (the standard treatment for the patient population enrolled in each cohort can refer to that for the phase II cohort study).
  • For phase II study, each cohort is defined as follows:

Cohort 1: Patients with locally advanced or metastatic non-small cell lung cancer with confirmed MET amplification or MET overexpression. Prior treatment should meet the following criteria: 1) If a previous test had identified an EGFR-sensitizing mutation (exon 19 deletion or exon 21 L858R mutation), the following requirements must be met: a) Disease progression after treatment with a third-generation EGFR-TKI and platinum-based chemotherapy ± /PD-L1 inhibitor, or intolerance to such treatment, or deemed unsuitable for platinum-based chemotherapy by the investigator; or b) Disease progression after first-or second-generation EGFR-TKI treatment with T790M mutation-negative or unknown gene mutation status, followed by disease progression after treatment with platinum-based chemotherapy ± PD-1/PD-L1 inhibitor, or intolerance to such treatment, or deemed unsuitable for platinum-based chemotherapy by the investigator. 2)If a previous test had identified an EGFR non-sensitizing mutation or MET exon 14 skipping mutation, disease progression after treatment with the corresponding inhibitors and platinum-based chemotherapy ± PD-1/PD-L1 inhibitor is required, or intolerance to such treatment, or deemed unsuitable for platinum-based chemotherapy by the investigator. 3)If no other driver gene alterations were identified in previous tests, disease progression after treatment with platinum-based chemotherapy ± PD-1/PD-L1 inhibitor is required, or intolerance to such treatment, or deemed unsuitable for platinum-based chemotherapy by the investigator.

Cohort 2: Patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (primary site in the oral cavity, oropharynx, hypopharynx, or larynx) with confirmed MET amplification or MET overexpression. Patients must have experienced disease progression or intolerance after previous treatment of platinum-based chemotherapy ± PD-1/PD-L1 inhibitor/EGFR monoclonal antibody therapy.

Cohort 3: Locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma (including signet ring cell carcinoma, mucinous adenocarcinoma, hepatoid adenocarcinoma) with detected MET amplification or MET overexpression. Prior treatment should meet the following criteria:1)Disease progression or intolerance after treatment with a chemotherapy regimen consisting of platinum agents (cisplatin or oxaliplatin),paclitaxel/docetaxel, and fluoropyrimidines (5-FU,capecitabine or S-1),with or without PD-1/PD-L1 inhibitor;2)For patients with positivity, disease progression after treatment with anti-HER-2 agents is required, or intolerance to such treatment, or deemed unsuitable for anti-HER-2 treatment by the investigator;3)For patients with Claudin 18.2 expression, disease progression after treatment with anti-Claudin 18.2 agents is required, or intolerance to such treatment.

  • Subjects in the phase I dose-exploration study must have evaluable lesions; other subjects (including dose-backfill stage in phase I and phase II) must have as per v1.1.
  • (ECOG) performance status of 0-1.
  • Expected survival ≥ 3 months.
  • Have adequate organ function (no blood transfusion or use of blood component or G-CSF support within 14 days before testing)
  • Willing and able to follow the trial and follow-up procedures.
  • Able to understand the nature of the trial and voluntarily sign the written form.

Exclusion criteria

Exclusion Criteria:

  • Subjects with non-small cell lung cancer who have been tested positive for ALK in the genetic tests conducted by the local or central laboratory.
  • Subjects have received any drug or antitumor agent (for drugs with a long half-life, the time interval since the last dose should be no more than 4 weeks; for chemotherapy with delayed toxicity, such as nitrosoureas or mitomycin C, within the previous 6 weeks) within 14 days prior to the first dose of the study drug or within 5 half-lives of the drug (whichever is longer). Subjects have used any traditional Chinese medicine or Chinese herbal preparations with antitumor indications or definitive antitumor effects within 14 days prior to the first dose of the study drug.
  • Subjects who have undergone any major surgery or radiotherapy within 4 weeks prior to the first dose of the study drug (palliative local radiotherapy is allowed if it was administered at least 2 weeks prior to the first dose of the study drug).
  • For subjects with non-small cell lung cancer, prior receipt of more than two is required; for subjects with squamous cell carcinoma of the head and neck and gastric cancer/gastroesophageal junction adenocarcinoma, prior receipt of more than three lines of systemic anti-tumor treatment (excluding maintenance therapy) is required. For subjects who have received /adjuvant therapy (chemotherapy or radio chemotherapy), if recurrence or occurs during treatment or within 6 months after discontinuation of treatment, it should be considered as first-line treatment.
  • Prior use of EGFR/c-Met bispecific antibody or ADC drugs.
  • Subjects who require concomitant use of strong inhibitors or inducers within 14 days before the first administration of the investigational drug or during the study period.
  • Toxicities related to prior treatment have not resolved to Grade 1 or below ( 5.0 criteria) prior to the first dose of the study drug, except for alopecia.
  • Subjects who have had other within the past 3 years, except for malignancies that have been clearly cured or are locally curable, such as basal or squamous cell skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast.
  • Cohort 1: Patients with primary central nervous system malignancy, or presence of meningeal metastases, or presence of spinal cord compression, or risk of cerebral hemorrhage, or symptomatic , or unstable brain metastases requiring treatment with and/or dehydration to reduce cranial pressure 2 weeks prior to enrollment.

Cohorts 2 and 3: Patients with known brain and/or meningeal metastases, or primary central nervous system malignancies are excluded. Subjects with neurological symptoms shall have a brain CT/MRI scan to exclude brain metastases.

  • Subjects with abnormal cardiovascular or cerebrovascular diseases, including but not limited to: Subjects with arterial thromboembolism, deep vein thrombosis, or pulmonary embolism within 3 months prior to the first dose of the study drug. Clinically insignificant non-obstructive catheter-related clots are not deemed as constituting an exclusion criterion. Subjects with a history of other venous thrombosis must be clinically stable for at least 4 weeks prior to the first dose of the study drug.

Subjects with any of the following medical history within 6 months prior to the first dose of the study drug: myocardial infarction, unstable angina, cerebrovascular accident, , transient myocardial ischemia, coronary or peripheral artery bypass grafting (including coronary intervention), or any acute coronary syndrome.

With abnormal interval (QTcF) of ECG at rest in the screening period, with the test been repeated twice at an interval 5 minutes above, and with the average QTcF of three ECG examinations: ≥ 450 msec for male, and ≥ 470 msec for female. Various clinically significant abnormalities in rhythm, conduction, resting ECG morphology within 3 months prior to the first dose of investigational drug, such as complete left bundle branch block, third degree block, second degree block, PR interval >250 msec, bigeminy, trigeminy, pre-excitation syndrome, ST-segment elevation, atrial fibrillation, ventricular fibrillation, etc.

Poorly controlled hypertension judged by investigators (systolic blood pressure > 180 mmHg, or diastolic blood pressure > 100 mmHg).

(NYHA) Class III-IV congestive heart failure (see Appendix 2) or hospitalization for congestive heart failure within 6 months prior to the first dose of investigational drug; (LVEF) \<50%.

Pericarditis/clinically significant pericardial effusion. Subjects with cardiomyopathy, including dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and myocarditis.

Subjects with other clinically significant cardiovascular or cerebrovascular diseases.

  • Subjects with active (HBsAg positive and serum HBV DNA quantitative results ≥ the lower limit of detection (as per criteria of local laboratory)); positive for anti- virus antibody, anti- antibody, or anti-treponema pallidum antibody (subjects with a history of HCV who have completed antiviral treatment and have laboratory test results showing HCV-RNA below the lower limit of quantification are eligible for enrollment; and subjects with negative syphilis titer tests are eligible for enrollment).
  • Subjects with a history of interstitial lung disease or current clinical evidence of interstitial lung disease/pneumonia, including but not limited to drug-induced interstitial lung disease/pneumonia, radiation pneumonitis, or pulmonary fibrosis. Patients who cannot exclude suspected interstitial pneumonia/pulmonary fibrosis or uncontrolled stable non-infectious pneumonia/pulmonary inflammation by imaging examination during screening are not eligible for enrollment.
  • Subjects with current severe illness or medical conditions, including but not limited to uncontrolled or poorly controlled active infections, uncontrolled pleural or peritoneal effusion, unstable tuberculosis, or other clinically significant pulmonary, metabolic, or psychiatric disorders.
  • Subjects with gastric cancer/gastroesophageal junction adenocarcinoma with signs of active bleeding, active gastrointestinal (GI) diseases, or risk of gastrointestinal (GI) perforation, or other diseases that can significantly interfere with the absorption, distribution, metabolism, or excretion of the investigational drug.
  • Subjects with hepatic encephalopathy, hepatorenal syndrome, or ≥ class B cirrhosis.
  • Women of with a positive serum pregnancy test within 7 days prior to the initiation of treatment, pregnant or breastfeeding women, and male or female subjects unwilling to use effective or plan for pregnancy during the entire treatment period and for 3 months after treatment completion (see Appendix 3 for guidelines on contraception).
  • Subjects with a history of allergy or suspected allergic symptoms to the study drug MCLA-129 or ensartinib or tartrazine (a dye used in ensartinib 100 mg capsules) or any other component or
  • Subjects judged by the investigator to have poor compliance, inability or unwillingness to adhere to the study and/or follow-up procedures listed in the protocol, or otherwise unsuitable for participation in this study.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Patients with locally advanced NSCLC.

    Patients with locally advanced NSCLC with previously detected EGFR-sensitizing mutations (exon 19 deletion or exon 21 L858R mutation) who have progressed after prior standard treatment and with MET amplification or overexpression. Drug: MCLA-129 and Ensartinib MCLA-129 will be administered intravenously at two different frequencies: 1500 mg every two weeks and 2000 mg every three weeks, in combination with Ensartinib. Ensartinib will be administered orally at 200 mg every day; if dose-limiting toxicity (DLT) is observed and deemed intolerable, a lower dose of 150 mg will be explored in combination with MCLA-129. Other Names: * MCLA-129 and Ensartinib Hydrochloride * MCLA-129 and Ensacove

    Drug: MCLA-129 · Drug: Ensartinib

  • Experimental
    Patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.

    Patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (primary site in the oral cavity, oropharynx, hypopharynx, or larynx) who have progressed after prior standard treatment and with MET amplification or overexpression. Drug: MCLA-129 and Ensartinib MCLA-129 will be administered intravenously at two different frequencies: 1500 mg every two weeks and 2000 mg every three weeks, in combination with Ensartinib. Ensartinib will be administered orally at 200 mg every day; if dose-limiting toxicity (DLT) is observed and deemed intolerable, a lower dose of 150 mg will be explored in combination with MCLA-129. Other Names: * MCLA-129 and Ensartinib Hydrochloride * MCLA-129 and Ensacove

    Drug: MCLA-129 · Drug: Ensartinib

  • Experimental
    Patients with locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma

    Patients with locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma (including signet ring cell carcinoma, mucinous adenocarcinoma, hepatoid adenocarcinoma) who have progressed after prior standard treatment and with MET amplification or overexpression. Drug: MCLA-129 and Ensartinib MCLA-129 will be administered intravenously at two different frequencies: 1500 mg every two weeks and 2000 mg every three weeks, in combination with Ensartinib. Ensartinib will be administered orally at 200 mg every day; if dose-limiting toxicity (DLT) is observed and deemed intolerable, a lower dose of 150 mg will be explored in combination with MCLA-129. Other Names: * MCLA-129 and Ensartinib Hydrochloride * MCLA-129 and Ensacove

    Drug: MCLA-129 · Drug: Ensartinib

Interventions

  • MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumor growth and survival.

  • Ensartinib acted as a c-MET inhibitor in this study.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT) in Phase I

    To evaluate the safety of MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors in terms of dose-limiting toxicity (DLT)

    Time frame: Until 28 days after the first dosing in MCLA-129 1500mg Q2W group or 21 days after the first dosing in MCLA-129 2000mg Q3W group

  2. Maximum Tolerated Dose (MTD) in Phase I

    To evaluate the safety of MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors in terms of maximum tolerated dose (MTD)

    Time frame: From date of first treatment until the end of Phase I, approximately 6 months

  3. Treatment-Emergent Adverse Events (TEAE) in Phase I

    To evaluate the safety of MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors in terms of treatment-emergent adverse event (TEAE)

    Time frame: From date of first treatment until 30 days after the last dose or the start of other anti-tumor treatment (whichever occurs first)

  4. Overall Response Rate (ORR) in Phase II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase II in terms of overall response rate (ORR)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

Secondary outcomes

  1. Clinical benefit rate (CBR) in Phase I and II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase I and II in terms of clinical benefit rate (CBR)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

  2. Disease Control Rate (DCR) in Phase I and II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase I and II in terms of disease control rate (DCR)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

  3. Progression-Free Survival (PFS) in Phase I and II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase I and II in terms of progression-free survival (PFS)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

  4. Duration of Response (DOR) in Phase I and II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase I and II in terms of duration of response (DOR)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

  5. Time to response (TTR) in Phase I and II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase I and II in terms of time to response (TTR)

    Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years

  6. Overall Survival (OS) in Phase II

    To evaluate the efficacy of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase II in terms of overall survival (OS)

    Time frame: From date of first treatment every 6 weeks until death or withdrawal, whichever came first, approximately 2 years

  7. Treatment-Emergent Adverse Event (TEAE) in Phase II

    To evaluate the safety of MCLA-129 in combination with Ensartinib hydrochloride at RP2D in patients with advanced solid tumors in each cohort in Phase II in terms of treatment-emergent adverse event (TEAE)

    Time frame: Until 30 days after the last dosing

  8. Area under the concentration versus time curve [AUC0-∞] in Phase I

    To evaluate the population PK profile of of MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors in terms of area under the concentration versus time curve \[AUC0-∞\]

    Time frame: Until 30 days after the last dosing

  9. Anti-Drug Antibody (ADA) in Phase I and II

    To assess the Incidence of anti-drug antibodies in serum blood against MCLA-129 following administration of MCLA-129

    Time frame: Until 30 days after the last dosing

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2026
First posted
Mar 4, 2026
StartActual
Jan 31, 2026
Primary completionEst.
Feb 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448116
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Jan 31, 2026
Primary completion
Feb 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Mar 4, 2026

Study contacts

Ming Ma, M.D.
Contact
ming.ma@bettapharma.com
+49 13927255392

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pamvatamig · Ensartinib

Start the discussion